Lupus Nexus: developing a prospective registry, biorepository and data exchange platform to foster global collaborations, accelerate research innovation and advance precision medicine in lupus Authors: Teodora P Staeva, Arezou Khosroshahi, Alfred Hyoungju Kim, Devon D Kelly, Mary Jo Fekete, Kechi Anyadike, Alyssa Baloski, Shannon K Barriteau, Amonte Davis, Angela M Mitchell, Nikolay Nepochatov, Grant Roesler, Melissa Rawley-Payne, William Apruzzese, Amanda Charbonneau, Christopher Dowd, Paul R Fortin, Paul Hoover, David R Karp, Fotios Koumpouras, Martin Lewis, Meggan Mackay, Paola Mina-Osorio, Christine Peschken, Jamie Shaw, Dayani Tipple, Zahi Touma, Albert Wang, Ruth Wilson, Stacie Bell, Alison Lee, Marc S Hurlbert, Jean Stimola-Sposaro, Virginia Pascual, Inaki Sanz, Peter Schafer, S Sam Lim, Lupus Landmark Study Investigators Published: 2026 ABSTRACT AbstractIntroductionSLE remains a disease of high unmet medical need. Protean manifestations and the lack of clear understanding of aetiology, pathogenesis and disease subgroups make it difficult to develop and employ targeted therapeutic approaches. Community-wide access to a longitudinal, highly curated patient dataset with linked biospecimens and cellular/molecular data is critical to enable advances and is now provided by Lupus Nexus (LNx). In this study, we describe the development of this unique resource with exemplary patient engagement.Methods and analysisLNx, developed with guidance from over 100 partners, includes a prospective, longitudinal observational study, the Lupus Landmark Study (LLS), that will enrol up to 3500 adults living with lupus into four cohorts and will follow them over 5 years. The registry data comprises medical information, clinician-reported and patient-reported outcomes while the biorepository includes whole blood, urine, saliva, stool and tissue which are available to the research community for a broad range of analyses. Importantly, since all raw data from the biospecimen analyses will be deposited in LNx, it will amass a deep and comprehensive dataset over time. As of 25 March 2026, there are 705 enrolled participants (13.3% new onset, 27.4% extrarenal flare, 23.3% active lupus nephritis and 35% prevalent cases, with 37.6% black, 38% white and 12.6% Asian/Pacific Islander patients). Over 15 400 unique samples have been collected and specific analyses are underway.All data and samples from LNx are available via its Data Repository Exchange and Analytics platforM (DREAM). Importantly, a dedicated patient portal within DREAM enables participants to view their study data, connect with others and learn about the research emerging from projects using LNx.Trial registration numberNCT05934149.Keywords: Systemic Lupus Erythematosus; Lupus Nephritis; Patient Reported Outcome Measures; Outcome Assessment, Health Care WHAT IS ALREADY KNOWN ON THIS TOPIC Established cohorts and consortia—including the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Inception Cohort, global academic lupus cohorts, the Accelerating Medicines Partnership (AMP) Rheumatoid Arthritis and Systemic Lupus Erythematosus, and AMP Autoimmune and Immune-Mediated Diseases (AMP AIM)—have advanced understanding of lupus pathogenesis and clinical heterogeneity. Established cohorts and consortia—including the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Inception Cohort, global academic lupus cohorts, the Accelerating Medicines Partnership (AMP) Rheumatoid Arthritis and Systemic Lupus Erythematosus, and AMP Autoimmune and Immune-Mediated Diseases (AMP AIM)—have advanced understanding of lupus pathogenesis and clinical heterogeneity. WHAT THIS STUDY ADDS A centralised operating model—combining diverse patient enrolment, expert clinical sites, a comprehensive data and analytics platform and best-in-class laboratories—coupled with a requirement to return raw analysed biosample data to the platform (after a defined exclusivity period) ensures high quality data (patient and molecular) of substantial scale and reuse potential beyond what single institutions can achieve. A centralised operating model—combining diverse patient enrolment, expert clinical sites, a comprehensive data and analytics platform and best-in-class laboratories—coupled with a requirement to return raw analysed biosample data to the platform (after a defined exclusivity period) ensures high quality data (patient and molecular) of substantial scale and reuse potential beyond what single institutions can achieve. Recruitment targets by race/ethnicity follow the prevalence distributions determined by the Centers for Disease Control and Prevention National Lupus Patient Registries (Izmirly et al), supporting equitable inclusion and generalisable findings. Recruitment targets by race/ethnicity follow the prevalence distributions determined by the Centers for Disease Control and Prevention National Lupus Patient Registries (Izmirly et al), supporting equitable inclusion and generalisable findings. Continuous patient engagement integrates lived experience throughout programme design and operations, including a community portal for both clinical study participants and non-participants to foster communication and insight generation. Continuous patient engagement integrates lived experience throughout programme design and operations, including a community portal for both clinical study participants and non-participants to foster communication and insight generation. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY By delivering high quality, representative, reusable and interoperable data, of considerable breadth and depth, Lupus Nexus will accelerate research discovery and clinical development, shape standards for data sharing, support clinical guidelines development and inform policies that promote equitable access and outcomes in lupus. By delivering high quality, representative, reusable and interoperable data, of considerable breadth and depth, Lupus Nexus will accelerate research discovery and clinical development, shape standards for data sharing, support clinical guidelines development and inform policies that promote equitable access and outcomes in lupus. Introduction SLE or lupus is a complex autoimmune disease with multifaceted and still poorly understood pathogenesis, diverse clinical manifestations and aberrant immunological responses.1 It is estimated that there are over 200 000 people living with SLE in the USA2 and many more worldwide.3 90% of people with SLE are female, and the disease is up to three times more prevalent in black or African American, American Indian and Alaska Native than white populations.2 Like other autoimmune diseases, lupus emerges from the convergence of genetic, environmental and immune factors. In SLE, the breakdown in immune tolerance to nuclear antigens leading to autoantibody formation and the activation of the type I interferon (IFN) system constitute the hallmark immune features.4 Immune complex deposition and chronic inflammation in many organs perpetuate the disease process characterised by periods of flares and remissions leading to organ damage accrual over time and increased mortality and morbidity when compared with the general population.5 Treatment options for lupus remain limited and lagging those for other autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis. While the lack of a more robust treatment armamentarium in SLE is due to a variety of factors,6 7 key among them is the vast disease heterogeneity (both between patients and within a patient over time) and the significant knowledge gaps in the understanding of disease mechanisms in people with lupus largely hindered by the lack of universally accessible longitudinal patient samples and data. The need for the lupus resource, whose establishment is detailed here, emerged at a 2018 Lupus Research Alliance (LRA)-convened meeting of global lupus, rheumatology, immunology and technology experts from academia, industry and government to identify lupus research challenges and prioritise opportunities that could accelerate SLE research and lead to new therapeutic advances. This forum identified disease heterogeneity as the fundamental issue in lupus critical to defining disease mechanisms and development of new treatments, and to understanding disease progression and response to therapy. It was felt that to make substantial advances in the field, heterogeneity must be tackled at every level—clinical, tissue, cellular and molecular—through the application of emerging technologies to patients’ samples and data. Yet, these were not readily available. There was a need for data and community integration, requiring extensive collaboration among academia and industry, and the engagement of patients with lupus as research partners. The LRA is the largest non-profit, non-governmental funder of lupus research globally.8 It is uniquely positioned to spearhead the establishment of an accessible registry, biosample repository and data exchange platform given its patient engagement efforts, Lupus Clinical Investigators Network (LuCIN)9 managed by LRA’s clinical affiliate, Lupus Therapeutics, the LRA Lupus Industry Council10 currently including 28 pharmaceutical and biotechnology companies and LRA’s close engagement with the lupus academic community through the Organisation’s long-standing research funding efforts. During the past 6 years, substantial progress has been made towards designing and establishing Lupus Nexus (LNx)11 (online supplemental figure 1), including the development of a framework (2019) followed by a community survey and a comprehensive business plan (2020), the empanelling of governing (Steering Committee) and advisory (seven Working Groups) bodies, the planning of the individual components of LNx and the selection of clinical sites and vendors to implement them. Conceptually, the establishment of LNx was guided by three overarching priority questions (online supplemental Table 1) developed by the Steering Committee and framed from a patient’s perspective: (1) What causes lupus as defined by the genetic drivers, environmental triggers and antigenic targets of SLE; (2) What type of lupus does a patient have as defined by the clinical and immune/molecular phenotypic heterogeneity, and informed by the patient experience, in diverse SLE populations; and (3) How will the disease progress as defined by the mechanistic correlates of severity and outcome, including therapeutic response. Importantly, LNx was designed to address both additional and emerging questions beyond those noted above to ensure the highest utility of this resource. In fact, research objectives will be delineated as a component of the analysis-specific projects submitted by investigators requesting access to LNx data and biospecimens. LNx comprises the following key components (figure 1): Lupus Landmark Study (LLS), clinical coordinating centre, biorepository and the Data Repository Exchange and Analytics platforM (DREAM). DREAM includes researcher/clinician and patient community portals and is enabled by high-performance computing. Best-in-class core and specialty laboratories ensure the highest quality data while companion diagnostics enhance the richness of the dataset. A quality management system underlies the entire infrastructure, ensuring its operational excellence and quality output. The Lupus Nexus structure comprises four main components, the Lupus Landmark Study, clinical coordinating centre, biorepository and DREAM. This manuscript describes the design, governance and early operational performance of LNx as a reusable, community-governed research infrastructure intended to support hypothesis-driven lupus research. Methods and analysis Study overview The LLS is the clinical study underlying LNx. The LLS is a prospective, longitudinal, observational study that will recruit 3500 adult patients with SLE from diverse backgrounds into four cohorts over the next 5 years and will follow them for at least 5 years collecting a variety of medical information, clinician-reported and patient-reported outcomes and a comprehensive set of biological samples (figure 2A,C). Since LNx is not powered for specific outcomes, the LLS cohort size was established based on balancing the goal for impact and the need for logistical feasibility. Recruitment is conducted through 24 of the 62 LuCIN9 sites in the USA and Canada (figure 2B). LuCIN is the premier network of lupus research medical centres in North America consisting of 62 sites, 250 rheumatologists and capturing 160 000 patients with lupus.12 The LLS was launched in May 2023 and has recruited, as of the writing of this manuscript, 705 individuals (figure 3A), a number that is continuously growing. The mean age of the study participants is between 36 and 44 years depending on the cohort (figure 3C). Importantly, the patients in the LLS are reflective of the broader lupus population and are highly diverse with only 38% of the cohort being white (figure 3B). Disease activity is widely distributed across participants’ study visits (figure 3D), while the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Damage Index is between 0 and 3 for most study visits to date (figure 3E). Substantial amounts of clinical data have been amassed (figure 3F). Importantly, patient retention remains robust at 95% two and a half years into the study (figure 3G). Lupus Landmark Study overview (A), clinical sites (B) and data collection elements (C). ACR, American College of Rheumatology; gDNA, genomic DNA; LLS, Lupus Landmark Study ; NPSLE, Neuropsychiatric Systemic Lupus Erythematosus; PBMC, Peripheral blood mononuclear cell; PGA, Physician Global Assessment; PROMIS, Patient-Reported Outcomes Measurement Information System; QOL, Quality of Life; SLAQ, Systemic Lupus Activity Questionnaire; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC, Systemic Lupus Erythematosus International Collaborating Clinics; VAS, Visual Analog Scale. Lupus Landmark Study recruitment statistics by cohort (A), planned versus actual recruitment within cohorts and demographics (B), age (C), SLEDAI-2K scores by study visit (D), SDI scores by study visit (E), clinical data points (F) and participant retention rates (G). ACR, American College of Rheumatology; Amer., American; LLS, Lupus Landmark Study; LN, lupus nephritis; SDI, Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/ACR Damage Index; SLEDAI-2K, SLE Disease Activity Index 2000. As of the writing of this manuscript, over 1373 sets of completed patient-reported outcomes (PROs) and 15 452 unique samples (participant × time point × sample type) (table 1A) have been collected. A fraction of these samples is currently being analysed through targeted, baseline multi-omic, autoantibody and blood medication level measurements generating foundational data to jumpstart broad community utilisation of LNx. All samples and data are available to the research and clinical community through the DREAM portal described below. Table 1Currently available Lupus Nexus samples (A) and pre-identified best-in-class laboratories for their analyses (B)(A) Currently available Lupus Nexus samplesSample typeMax. # aliquotes per visitAliquot countUnique aliquotsUnique participantPBMC from WB-ACDA810 3601448602Granulocytes from WB-ACDA1 @ baseline only551544533PaxDNA for WGS1 @ baseline only675658658PaxRNA233841687659Plasma from WB-ACDA569201443601Plasma (EDTA)581911688662Serum (SST)812 2321687661Urine—whole232351581651Urine—cells462071562649Urine—supernatant348411579650Stool3870405266Saliva111871170636Total58 65315 452 (B) Pre-identified best-in-class laboratories for their analyses Assay Best-in-class laboratory Whole genome sequencing*Broad InstituteBulk RNA sequencing*GENEWIZBulk TCR and BCR sequencing*iRepertoireProteomics*Olink via AzentaAuto-antibody measurements*University of Calgary, Choi LaboratoryMicrobiome metagenomics*Cmbio/CosmosIDTherapeutic medication levels*LabCorpSingle-cell RNA sequencingAzentaSpectral flow cytometryKCAS BioCyToFStandard BioTools*Assays included in the Lupus Nexus Foundational Analyses.BCR, B cell receptor; CyToF, Cytometry by time of flight; PaxDNA, PAXgene Blood DNA tube; PaxRNA, PAXgene Blood RNA tube; PBMC, Peripheral blood mononuclear cell; SST, Serum separator tube; TCR, T cell receptor; WB-ACDA, Whole Blood Acid Citrate Dextrose - solution A; WGS, whole genome sequencing. Currently available Lupus Nexus samples (A) and pre-identified best-in-class laboratories for their analyses (B) Assays included in the Lupus Nexus Foundational Analyses. BCR, B cell receptor; CyToF, Cytometry by time of flight; PaxDNA, PAXgene Blood DNA tube; PaxRNA, PAXgene Blood RNA tube; PBMC, Peripheral blood mononuclear cell; SST, Serum separator tube; TCR, T cell receptor; WB-ACDA, Whole Blood Acid Citrate Dextrose - solution A; WGS, whole genome sequencing. Patient population, eligibility and recruitment strategy Disease manifestations included in this study were based on the LNx priority questions (online supplemental Table 1), its forward-looking nature and intended community-wide use of this resource. The inclusion criteria for the overall SLE registry and biorepository population and its cohorts include ability to understand and comply with study procedures and voluntarily sign a written informed consent document, age 18 or older at time of enrolment, ability to fulfil all study procedures and requirements of enrolment/baseline visit, and fulfil criteria for SLE based on one or more of the following classification systems: SLICC 2012 criteria,13 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 criteria,14 1997 revised ACR criteria.15 Exclusion criteria include inability to obtain consent and/or meet protocol visit requirements and being pregnant at the time of enrolment. However, if a participant becomes pregnant during the study, they will continue participation and pregnancy outcomes will be collected. The LLS is currently enrolling individuals with SLE into one of four cohorts (figure 2A), each with its own inclusion/exclusion criteria and schedule of events: (1) New onset SLE (within 12 months of diagnosis); (2) active lupus nephritis (LN) (renal biopsy to verify LN within 12 months showing class II, III/IV±V or class V; for those with clinically suspected and active LN with intention to treat per the treating physician but unable to obtain a kidney biopsy, additional support from the treating physician must be submitted); (3) extrarenal lupus flare (flare, within 30 days preceding enrolment into the study, meeting definition in consensus statement16); and (4) prevalent SLE cases (not meeting inclusion criteria for any of the other three cohorts and negative for flare at entry). It should be noted that the extrarenal cohort excludes patients with only a renal flare, that is, there is no overlap at recruitment between the cohorts although cohort switching can occur during the study depending on the evolution of participants’ disease course. To ensure a geographically diverse patient population in the LLS, study participants are recruited from LuCIN clinical sites9 across the USA and Canada (figure 2B). Additionally, given that SLE disproportionately affects non-white groups, representation of minority populations is a central aspect of this study. The LLS enrolment targets based on race/ethnicity follow the distributions determined by the Centers for Disease Control and Prevention National Lupus Patient Registries.2 The target LLS recruitment based on race and ethnicity is shown in figure 3B. To reduce inherent recruitment bias, strategies to ensure balance in participant representation (based on patient-reported race and ethnicity) are employed, and enrolment target metrics are closely monitored. The focus is on the non-white patient population distribution with the goal of meeting or exceeding those proportions. The LLS is currently on target or close to target for most categories (figure 3B). Those (new onset, prevalent, American Indian/Alaska Native and Hispanic/Latino) currently slightly off the prespecified targets partially reflect the early stage of the LLS and the staggered and ongoing clinical site activation representing different catchment areas. The considerable number (4.1%) of participants with ‘unknown’ gender reflects a partial delay in the data upload due to a process switch and will be resolved by mid-2026. Study procedures The yearly schedule of events (table 2) related to data and biospecimen collections is designed for each cohort and is based on the anticipated frequency of standard of care (SOC) visits (table 2A). Study participants will also be seen within 2 weeks of a flare. A flare may require initiating more frequent follow-up, reverting to the year 1 schedule of events within the same cohort or may necessitate reassigning the participant to a different cohort and subsequently following the schedule of events of the new cohort, starting at the month 3 visit. Table 2LLS visit schedule per cohort (A), year 1 SOE data collection (B), PROs (C) and laboratory assessments and procedures (D) (A) LLS visit schedule per cohort Visit schedule Cohort Year 1 Year 2 Year 3 Year 4 Year 5 Flare New onset521-21-21-2xLupus nephritis54221-2xExtrarenal flare521-21-21-2xPrevalent21111x (B) Year 1 SOE data collection Procedure Enrolment (baseline) Year 1 In-person 4 visits (q3 month±1 month) Flares/ unscheduled (within 2 weeks of flares) Month 0 3 6 9 12 Informed consentXInclusion/exclusion criteriaXContact informationXUpdated contact informationXXXXXFull medical history/physical examinationXUpdated medical historyXXXXXFamily autoimmune historyXUpdated family autoimmune historyXPhysician rated (CLINROs)Disease activity: SLEDAI-2K; PGA; flare componentsXXXXXXDamage Index: SDIXPast/current medications and dosagesXChange in medications and dosagesXXXXXVaccinationsXXXXXXNPSLEXXXXXX (C) PROs Tool or questionnaire Time (Approximate minutes) Enrolment (baseline) Year 1 4 in-person visits Flares/ unscheduled (within 2 weeks of flares) Month: 0 3 6 9 12 SLAQ10XXXXXXPROMIS fatigue SF7a1–2XXXXXXFatigue by VAS1XXXXXXPROMIS pain interference1XXXXXXPain by VAS1XXXXXXPROMIS physical function1XXXXXXPROMIS depression2XXXXXXPROMIS Anxiety1XXXXXXBrain Fog Questionnaire1XXXXXXPerceived Stress Scale2–3XXXXXXAdherence—ad hoc instrument1XXXXXXPhysical activity—ad hoc instrument1XXXXXXPROMIS sleep disturbance short form1-2XXXXXXLupusQoL2–5XXXXXXFull demographics5XSocial history/determinants of health5–10XXXXXHealth habits5XXX (D) Laboratory assessments and procedures Laboratory assessments and procedures Volume (cc) Enrolment (baseline) 1 Year 1 in-person 4 visits (q3 month±1 month) Flares/unscheduled (within 2 weeks of flares) Month 0 3 6 9 12 Genomic DNA (whole blood)2.5XRNA (whole blood)5XXXXXXPlasma2XXXXXXSerum8XXXXXXPBMCs25.5XXXXXXUrine50 mLXXXXXXSaliva1XXXXBlood (capillary)100 µLXXXXXXKidney biopsyFor LN cohort only: For patients who opt into extra research samples and for sites that are able, an additional renal core biopsy at every opportunity is critical.StoolXXXXACR, American College of Rheumatology; CLINROs, Clinician Reported Outcomes; LLS, Lupus Landmark Study; LN, Lupus Nephritis; Lupus QoL, Lupus Quality of Life; NPSLE, Neuropsychiatric Systemic Lupus Erythematosus; PBMCs, Peripheral blood mononuclear cells; PGA, Physician Global Assessment; PROMIS, Patient-Reported Outcomes Measurement Information System; PROs, patient-reported outcomes; SDI, SLICC/ACR Damage Index; SF7a, PROMIS Fatigue Short Form 7a ; SLAQ, Systemic Lupus Activity Questionnaire ; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC, Systemic Lupus Erythematosus International Collaborating Clinic; SOE, schedule of events; VAS, Visual Analog Scale. LLS visit schedule per cohort (A), year 1 SOE data collection (B), PROs (C) and laboratory assessments and procedures (D) ACR, American College of Rheumatology; CLINROs, Clinician Reported Outcomes; LLS, Lupus Landmark Study; LN, Lupus Nephritis; Lupus QoL, Lupus Quality of Life; NPSLE, Neuropsychiatric Systemic Lupus Erythematosus; PBMCs, Peripheral blood mononuclear cells; PGA, Physician Global Assessment; PROMIS, Patient-Reported Outcomes Measurement Information System; PROs, patient-reported outcomes; SDI, SLICC/ACR Damage Index; SF7a, PROMIS Fatigue Short Form 7a ; SLAQ, Systemic Lupus Activity Questionnaire ; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC, Systemic Lupus Erythematosus International Collaborating Clinic; SOE, schedule of events; VAS, Visual Analog Scale. A variety of medical and clinician-reported data are collected (table 2B). Central nervous system (CNS) and neuropsychiatric events related to SLE will be captured among all participants in this study, including potential contributors, treatment recommendations and diagnostic testing. Types of neuropsychiatric events to be captured include peripheral nervous system and CNS manifestations (including diffuse and focal events). The categorisation of central and peripheral system events will be based on ACR Neuropsychiatric Systemic Lupus Erythematosus syndromes.17 PROs (table 2C) are collected using a web portal and smartphone applications taking approximately 30 min in total for each participant to complete. Post baseline, visits and data and sample collections occur in accordance with the individual cohort schedule (table 2A). The noted schedule of events (table 2B-D) applies to all cohorts in year 1, except the prevalent where visits occur at enrolment, 6 months and 12 months. The same assessments/procedures occur in subsequent years but with frequencies in accordance with the visit schedule (table 2A). Based on the visit and cohort, participants may have blood, urine, saliva and stool samples collected for specialty laboratory analyses and biorepository storage for use by the broader scientific community (table 2D). Diagnostic remnant biospecimens collected as part of SOC (eg, biopsy tissue, cerebrospinal fluid, synovial fluid) may also be submitted to the biorepository for future research purposes. Additional, non-invasive specimen collections, including finger stick blood samples and stool collections, are performed via home test kits supplied to participants. Available samples, best-in-class laboratories and initial analyses As of 25 March 2026, LNx has amassed 15 452 unique samples (participant × time point × sample type) from a variety of sample types (table 1A). Following an open, competitive review process, best-in-class laboratories were selected for the following assessments: whole genome sequencing (WGS), whole blood bulk and Peripheral blood mononuclear cell (PBMC) single-cell RNA sequencing, T Cell Receptor (TCR)/B Cell Receptor (BCR) sequencing, proteomics, autoantibody levels, PBMC multispectral flow cytometry and Cytometry by time-of-flight (CyToF), stool metagenomics and hydroxychloroquine (HCQ) medication levels (table 1B). Barring any special circumstances, utilisation of these best-in-class laboratory studies will be required for LNx users to ensure the highest data quality and consistency. Collaborations with select companion diagnostic companies are providing additional data into the platform that is of value to both patients and clinicians/researchers. For example, DxTerity is performing its Modular Immune Profile assay18 on fingerpick blood samples collected by participants at home using the DxCollect MicroCollection Device mailer kits. DxTerity is contributing the assay report and raw data for IFN high/low status, B-cells high/low status and readouts for 10 type I IFN genes to the LNx DREAM. A key LNx feature differentiating it from similar efforts is the requirement for return of raw data from the analyses of all biological samples. Following a 12-month exclusivity period (governed by the LNx Access Policy), the raw data will be made available to all end users of the LNx DREAM. As a result, it will amass over time an unprecedented depth of molecular data coupled with clinician-reported and patient-reported data and electronic health records. Jumpstarting these analyses is a concerted Foundational Analyses effort, using some of the best-in-class laboratory studies (table 1B), that will generate WGS, whole blood bulk RNA sequencing and TCR/BCR sequencing, proteomics, auto-antibody levels, stool metagenomics and HCQ levels data on the baseline LLS samples enabling the development of hypothesis-testing LNx projects by the broader research community. The first data emerging from the Foundational Analyses is expected to be available in DREAM in mid-2026. Future use The LLS is organised to facilitate future use of data and biospecimens to answer specific research and clinical questions or objectives critical to understanding the clinical journey of participants with SLE. The LRA is the sponsor of the study and is accountable for database and biorepository administration. Coded samples and data from this study are available to the entire research community, through the DREAM portal, to perform scientific analyses or conduct more research that can help advance medical science and/or improve patient care. Importantly, LLS substudies and other clinical studies could be added to LNx to expand utility and maximise impact. The LRA stewards the LNx/LLS data on behalf of participants under the terms approved by institutional review boards (IRBs) and consent documents. However, any new data generated by investigators using the LNx samples/data are owned by the investigator(s) conducting the experiments. Similarly, any new intellectual property generated by investigators using samples/data from the LNx belongs to the investigator making the discovery and her/his organisation. Statistical methodology The purpose of this study is to establish a registry and biorepository from which future research studies will be based. Investigators wishing to analyse biospecimens collected as part of this protocol will be required to submit sample access requests including sample size calculations to justify the proposed analyses. Submissions will undergo review and approval by the LNx Scientific Review Committee which will require future analyses to be hypothesis-driven, use prespecified statistical plans and control for site clustering and repeated measures to uphold the scientific rigour of LNx and ensure that future studies make the best use of this rich resource. Additionally, if there is potential for synergy among separate applications, researchers with similar concurrent proposals will be asked to consider collaboration/coordination of efforts and/or sharing of analyses to prevent duplication and maximise the use of biological samples. A list of ongoing projects will be available on the LNx website, and should researchers wish to conduct a project that is already ongoing they will be advised to wait until the raw data from the ongoing analysis is made available on DREAM within 12 months or less of the completion of the analysis. An LNx access policy has been developed and will guide these decisions. LLS status As of the writing of this manuscript, the LLS has recruited a total of 705 participants (figure 3A) and is tracking relatively close to the target recruitment numbers for race, ethnicity, gender and cohort (figure 3B). Adjustments are continually made to recruitment to ensure that the targets are met in the overall cohort. In addition, robust patient engagement activities as detailed below have contributed to a retention rate of 95% (figure 3G) two and a half years into the study. The data and samples (table 1A) acquired through the LLS can be accessed via the LNx DREAM, www.lupusnexus.org. Patient and public involvement statement Individuals living with lupus were involved in LNx from inception and have been continuously and prominently engaged ever since. This is one of the key strengths and unique features of the programme. Patient representation has been included on the LNx Steering Committee since its launch. A Patient Engagement Working Group was empanelled in 2021 to provide patient perspective on all aspects of LNx development including defining the patient journey, providing input on recruitment and retention strategies to ensure patient engagement over time, providing guidance on meeting diversity targets and making the study convenient for patients. The group also advised on data privacy requirements of the patient community, the patient portal development, the return of research results to patients and any marketing, educational materials or incentives used in the recruitment, retention and engagement of patients. Following the launch of the LLS, the Patient Engagement Working Group was replaced by the Patient Advisory Group which provides ongoing oversight and guidance on all patient-related activities of the programme (eg, recruitment and retention strategies, educational materials, web portal accessibility). Both the Patient Engagement Working Group and the Patient Advisory Group (PAG) are comprised and led entirely by individuals living with lupus. All members of these groups are compensated for their time and the groups’ leaders are included as coauthors in this publication. In addition, the PAG members were included as authors in a recent LNx ACR meeting abstract.19 Dissemination All data and samples from LNx are available via its DREAM platform (https://dreamcommunity.lupusresearch.org/b/researchers). Data generated from the use of biospecimens is required to be deposited into the DREAM, thereby enriching the resource over time. The LNx programme encourages all scientific discoveries to be published by researchers and has developed a Publication Policy to support these efforts. Importantly, a dedicated patient community portal (https://dreamcommunity.lupusresearch.org/) will enable participants to view their study data, connect with others and learn about the research emerging from projects using LNx. Discussion LNx is now established as a collaborative registry, biorepository and data exchange platform offering the community access to prospective, longitudinal clinical data, patient-reported outcomes and linked biospecimens at a scale not achievable by single institutions. Its centralised model and continuously increasing data depth (as raw data from the biosample analyses are returned to the platform) are designed to accelerate translational research and support more representative, clinically actionable insights. Importantly, the requirement for return of raw data from the analyses of all LNx samples back to the DREAM following a 12-month exclusivity period is a key structural innovation that could serve as a model for future National Institutes of Health/industry partnerships. Overall, LNx is building a robust, more integrated, collaborative and connected lupus community inclusive of patients, clinicians and researchers. Patient partnership is embedded throughout LNx and the LLS. People living with lupus helped shape protocol design and operations, contributing to a 95% participant retention rate two and a half years into the study. LNx is built to return research results to participants and, through the DREAM community portal, supports a broader patient community that includes both participants and non-participants. LLS complements randomised controlled trials by enrolling populations often excluded from intervention studies, including patients with lower disease activity (eg, SLEDAI-2K (SLE Disease Activity Index 2000) ≤6) and those with significant comorbidities such as NPSLE (when able to consent). As a result, LNx will fill key knowledge gaps in understudied phenotypes and inform precision medicine approaches across the full spectrum of disease. LNx also complements existing lupus cohorts and consortia efforts by offering additional breadth and scale. Importantly, it leverages the existing external resources by enabling cross-linkages (when allowed by the external source) and data integration. Current limitations of LNx include the academic-centre bias, lack of healthy controls (HC) and active flare surveillance, early stage of the study and the inherent uncertainties this brings and potential challenges of harmonising multi-omics datasets. Since recruitment is through academic centres part of LuCIN, there is a potential limitation in representativeness of community-based underinsured populations. This may be partially offset by planned future expansion of the registry component of LNx to include practices in underserved communities. The establishment of an HC cohort is under consideration and should add a valuable component to LNx. The lack of active flare surveillance and the reliance on clinic visits and patient reporting may affect time-to-event analyses. The LLS is not powered to address specific outcomes with prespecified clinical endpoints, which would require appropriate statistical power or sample size calculations. Time-to-flare, organ-specific progression, damage accrual, treatment response and relatively rare but meaningful clinical events, such as NPSLE, are examples of specific outcomes. Longitudinal data on these outcomes will be available in the LLS, but the study was neither designed nor powered (in terms of sample size, event rate or duration of follow-up) to allow definitive inferences about any single endpoint across all subgroups of interest. The LLS is designed to be a discovery-generating and hypothesis-generating resource. The richness of phenotyping in a large, diverse, longitudinally followed cohort that includes groups traditionally under-represented in clinical trials will enable researchers to conduct trajectory-based analyses (via repeated measures over time) and within-subject inference. Coupling that with the availability of multi-omic data allows molecular discoveries to be linked to the clinical phenotype. These properties allow the LLS to be used for candidate biomarker discovery/prioritisation, prediction model building, phenotype clustering, etc. The generation of specific hypotheses can then be tested. We fully expect these types of confirmatory analyses on specific clinical outcomes to be enabled by (1) ongoing accrual in LNx, (2) substudies designed within the LLS with prespecified outcomes and appropriate power calculations and (3) linkage with external datasets that have formal outcome adjudication. Near-term priorities within the existing framework include bolstering the renal biopsy collection in the lupus nephritis cohort, enhancing stool sample collection across groups, adding healthy controls and evaluating the feasibility of establishing a cutaneous lupus cohort. Longer-term opportunities, contingent on resources, include international expansion and collaborations in related conditions (eg, Sjögren’s disease). LNx is positioned to enable big-data analytics and artificial intelligence applications by addressing common barriers—dataset size and diversity, interoperability and secure compute. The DREAM platform provides a unified environment to integrate multimodal data (-omics, biorepository metadata, Electronic Health Records/clinical/PRO), support data sharing and enhance data analysis by allowing researchers to bring additional software tools to the platform. This infrastructure is intended to generate fundamental insights into human lupus heterogeneity, yield validated models (eg, flare prediction, treatment response), biomarker panels, and trial enrichment strategies. By linking molecular heterogeneity to clinical phenotypes and incorporating patient-reported outcomes, LNx will help the community generate mechanistic insights, identify actionable biomarkers, design more efficient, inclusive trials and improve the standard of care. Ultimately, LNx will shorten the path from discovery to improved treatments and care for diverse populations disproportionately affected by lupus. Supplementary material